Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CTH | P32929 | 2/20 | 0.42 |
| ▸ | CBS | P35520 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28386959 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL22806980 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL1594769 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL26111100 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL13599228 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL1170690 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL60430 | 1.00 | TSHR (0.42) | TSHRCTHCBSTHPOTHRB | |
| Hydrochloric Acid SCHEMBL9788713 | 0.98 | THRB (0.44) | TSHRCTHCBSTHPOTHRB | |
| Hydrochloric Acid SCHEMBL17941286 | 0.98 | THRB (0.44) | TSHRCTHCBSTHPOTHRB | |
| SCHEMBL303946 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125428-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIV CONNECTICUT (US) | 2026-05-07 | — | — | US | claimed |
| US-12600749-B2 | Compstatin analogues and their medical uses | ZP SPV 3 K/S (DK) | 2026-04-14 | — | — | US | claimed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | claimed |
| US-20260092085-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIV CONNECTICUT (US) | 2026-04-02 | — | — | US | claimed |
| US-20260069653-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | APELLIS PHARMACEUTICALS INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-20240318240-A1 | TARGET NUCLEIC ACID AMPLIFICATION METHOD USING GUIDE PROBE AND CLAMPING PROBE AND COMPOSITION FOR AMPLIFYING TARGET NUCLEIC ACID COMPRISING SAME | HLB PANAGENE CO., LTD. (KR) | 2024-09-26 | — | — | US | claimed |
| US-20240309046-A1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | ZEALAND PHARMA A/S (DK) | 2024-09-19 | — | — | US | claimed |
| EP-4426327-A2 | COMPLEMENT INHIBITOR DOSING REGIMENS | Apellis Pharmaceuticals, Inc. (US) | 2024-09-11 | — | — | EP | claimed |
| US-20240285725-A1 | DOSING REGIMENS | SIXTH STREET LENDING PARTNERS | 2024-08-29 | — | — | US | claimed |
| US-20150141660-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | claimed |
| US-20150119330-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2015-04-30 | — | — | US | claimed |
| EP-2844246-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | The Board of Regents of the University of Oklahoma (US) | 2015-03-11 | — | — | EP | claimed |
| EP-2616808-B1 | PROLYL ENDOPEPTIDASE PROBES | STANFORD RES INST INT (US) | 2015-02-25 | — | — | EP | claimed |
| US-8933201-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-01-13 | — | — | US | claimed |
| WO-2013166438-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2013-11-07 | — | — | WO | claimed |
| EP-2616808-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI International (US) | 2013-07-24 | — | — | EP | claimed |
| WO-2012037044-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI INTERNATIONAL (US) | 2012-03-22 | — | — | WO | claimed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | claimed |
| US-20110144037-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | TSHR 1283/4885CTH 1257/4885CBS 236/4885 |
| US-20240309046-A1 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | C1QBP, C9, VIP | TSHR 1041/4885CTH 468/4885CBS 1263/4885 |
| US-20260092085-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | TPX2, BCL2L11, U2SURP | TSHR 1771/4885CTH 1508/4885CBS 2341/4885 |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | PREP, XPNPEP1, ANPEP | TSHR 1945/4885CTH 1037/4885CBS 2706/4885 |
| US-12600749-B2 | Compstatin analogues and their medical uses | NGLY1, C9, C1QBP | TSHR 238/4885CTH 361/4885CBS 904/4885 |
| US-20240285725-A1 | DOSING REGIMENS | C3AR1, C1QBP, C9 | TSHR 1494/4885CTH 907/4885CBS 1271/4885 |
| US-20260125428-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | MYC, MYCBP, PCNA | TSHR 1367/4885CTH 3786/4885CBS 3382/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | TSHR 17/4885CTH 4/4885CBS 14/4885 |
| US-20260069653-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | CFD, C5, C1QBP | TSHR 1278/4885CTH 1909/4885CBS 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.